Uc Ibd Clinical Data Registry
Posted Date: Oct 15, 2024
- Investigator: Anita Afzali
- Specialties:
- Type of Study: Observational/Survey
IBD can be a severe and disabling disease with potentially serious complications including need for surgical intervention, nutritional deficiencies, and poor mental health. There has been progress in discussion, study, and research of IBD, but there are continuing opportunities for earlier detection of an accurate diagnosis, personalized treatment and improved quality of life. Inflammatory bowel disease is a complex and chronic autoimmune disease that requires a multidisciplinary team approach utilizing pharmacologic and nonpharmacologic treatments. For many patients, biologic therapy is required to decrease bowel inflammation and improve overall quality of life for IBD patients. Over the years, there have been great advances in research leading to a larger medicine cabinet of biologic therapies showing great efficacy and safety. We currently have various biologic MOAs and this continues to grow with more evidence attained from clinical trials, but most of our current recommendations for biologic positioning comes from expert opinion. There are only two significant head-to-head trials (VARSITY, SEQUENCE) that have shown biologic superiority. As we make treatment advances with head-to-head trials and network meta-analysis, there continues to be room for improvement in maintaining long-term clinical and endoscopic remission for IBD patients. This data registry will provide substantial data that will be utilized for future research projects to improve treatment leading to long-term clinical and endoscopic remission with overall improvement in quality of life for IBD patients.
Criteria:
Any Patient Seen In Uc Health System With A Diagnosis Of Ibd (Inflammatory Bowel Disease)
Keywords:
Ibd, Crohn's, Ulcerative Colitis
For More Information:
Rebecca Crum
NULL
crumra@ucmail.uc.edu